Masitinib Studies Suspended Over Ischemic Heart Disease Risk
https://pixabay.com/en/anatomy-human-heart-pulse-frequency-2328534/

Masitinib Studies Suspended Over Ischemic Heart Disease Risk

Altogether, AB Science has been evaluating a tyrosine kinase inhibitor, masitinib, for a variety of conditions including amyotrophic lateral sclerosis (ALS), COVID-19, and mastocytosis. But according to ALS News Today,…

Continue Reading Masitinib Studies Suspended Over Ischemic Heart Disease Risk
The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
source: pixabay.com

The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases

  A recent article in the Encinitas Advocate heralded the dedication of Stan Crooke, n-Lorem Foundation’s CEO and founder. The nonprofit Foundation’s team acts as middlemen, working with patients who…

Continue Reading The N-Lorem Foundation is Developing Treatments for Patients With Ultra-Rare Diseases
New $15M Effort to Expand ALS Research and Find Biomarkers
https://pixabay.com/en/dollar-money-currency-trade-1974694/

New $15M Effort to Expand ALS Research and Find Biomarkers

Target ALS has recently launched a new research initiative, in which they will dedicate $15 million to amyotrophic lateral sclerosis (ALS) research, specifically the discovery of biomarkers. These millions will…

Continue Reading New $15M Effort to Expand ALS Research and Find Biomarkers
New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life
source: pixabay.com

New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

Dilated cardiomyopathy is a heart condition caused by a mutation in the RBM20 gene. This heart condition is unique because it can affect young adults. These individuals are at an…

Continue Reading New Discovery Allows Researchers to Study Mechanisms in Neurodegenerative Diseases from Beginning of life

New Collaboration: Scribe Therapeutics and Biogen to Explore CRISPR-Related Therapies for ALS

On October 6, 2020, molecular engineering company Scribe Therapeutics announced an exciting partnership. Originally founded by molecular engineers and CRISPR inventors, Scribe Therapeutics seeks to develop in vivo genetic medicine to treat…

Continue Reading New Collaboration: Scribe Therapeutics and Biogen to Explore CRISPR-Related Therapies for ALS
Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN
Photo by Robina Weermeijer on Unsplash

Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN

  According to a press release, biopharmaceutical company Apellis Pharmaceuticals ("Apellis") recently launched registration programs to explore pegcetacoplan for patients with C3 glomerulopathy (C3G), amyotrophic lateral sclerosis (ALS), and immune…

Continue Reading Pegcetacoplan Registrational Programs Begun for C3G, ALS, and IC-MPGN
Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete
source: pixabay.com

Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

According to a story from BioSpace, the biopharmaceutical company Clene Nanomedicine, Inc., has recently announced that it has completed the process of enrollment patient participants in its upcoming phase 2…

Continue Reading Enrollment for Phase 2 Amyotrophic Lateral Sclerosis Trial is Complete

Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases

According to a recent article in MedicalXpress, researchers in Japan led by Dr. Shinsuke Ishigaki and his team at Nagoya University, have identified new molecular details about tau’s activity. Alzheimer’s,…

Continue Reading Researchers at Nagoya University are One Step Closer to Unraveling the Tau Mystery in Neurodegenerative Diseases
Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease
Source: Pixabay

Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease

  Within the last month, BrainStorm Cell Therapeutics Inc. announced the publication of pre-clinical data on the NurOwn system. NurOwn technology produces autologous, bone marrow-derived mesenchymal stem cells (MSCs) for…

Continue Reading Preclinical Data Supports NurOwn for ALS, MS, and Alzheimer’s Disease